奥马环素治疗感染的初步、真实世界、多中心经验
Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.
作者信息
Morrisette Taylor, Alosaimy Sara, Philley Julie V, Wadle Carly, Howard Catessa, Webb Andrew J, Veve Michael P, Barger Melissa L, Bouchard Jeannette, Gore Tristan W, Lagnf Abdalhamid M, Ansari Iman, Mejia-Chew Carlos, Cohen Keira A, Rybak Michael J
机构信息
Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Division of Pulmonary and Critical Care Medicine, University of Texas Health Science Center, University of Texas, Tyler, Texas, USA.
出版信息
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
Abstract
Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for . The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
摘要
12名患者接受了奥马环素（OMC）治疗，作为多药治疗方案的一部分用于……。大多数感染起源于肺部（7/12；58.3%）。奥马环素治疗的中位（四分位间距）持续时间为6.2（4.2 - 11.0）个月。9/12（75.0%）的患者临床治疗成功。3名患者在治疗期间出现了可能的不良反应。
相似文献
1
Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections.奥马环素治疗感染的初步、真实世界、多中心经验
Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.
2
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.替加环素、依拉环素、奥马环素和沙雷环素对快速生长分枝杆菌的抗菌活性。
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.
3
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.奥马环素治疗非结核分枝杆菌感染的临床疗效和安全性的长期评估：一项回顾性、多中心真实世界健康结局的队列研究。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0082423. doi: 10.1128/aac.00824-23. Epub 2023 Sep 28.
4
Long-term Safety and Tolerability of Omadacycline for the Treatment of Infections.奥马环素治疗感染的长期安全性和耐受性
Open Forum Infect Dis. 2023 Jul 3;10(7):ofad335. doi: 10.1093/ofid/ofad335. eCollection 2023 Jul.
5
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.奥马环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
6
Omadacycline for the Treatment of Disease: A Case Series.奥马环素治疗疾病：病例系列
Open Forum Infect Dis. 2020 Sep 9;7(10):ofaa415. doi: 10.1093/ofid/ofaa415. eCollection 2020 Oct.
7
Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series.奥马环素一线联合治疗肺脓肿分枝杆菌感染：病例系列研究。
Int J Infect Dis. 2022 Sep;122:953-956. doi: 10.1016/j.ijid.2022.06.061. Epub 2022 Jul 4.
8
Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus.奥马环素与其他抗菌药物联合对脓肿分枝杆菌的协同作用。
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0157922. doi: 10.1128/aac.01579-22. Epub 2023 May 8.
9
Omadacycline therapy for Mycobacterium abscessus species infections.美满霉素治疗脓肿分枝杆菌感染。
Intern Med J. 2023 Dec;53(12):2257-2263. doi: 10.1111/imj.16071. Epub 2023 Mar 25.
10
Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.奥马环素治疗脓肿分枝杆菌感染：有效性评价、治疗地位及应用考量。
BMC Infect Dis. 2022 Nov 22;22(1):874. doi: 10.1186/s12879-022-07857-7.
引用本文的文献
1
Drug susceptibility profiles of isolated in the state of São Paulo, 2008-2024.2008年至2024年在圣保罗州分离出的菌株的药敏谱。
J Med Microbiol. 2025 Apr;74(4). doi: 10.1099/jmm.0.002005.
2
Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System.使用美国食品药品监督管理局不良事件报告系统对药物性低纤维蛋白原血症进行药物警戒分析。
Int J Clin Pharm. 2025 Jan 31. doi: 10.1007/s11096-025-01867-6.
3
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).抗菌药物新视角：奥马环素用于社区获得性肺炎、皮肤及软组织感染和非结核分枝杆菌（重点论述）
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0108724. doi: 10.1128/aac.01087-24. Epub 2025 Jan 16.
4
Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.利用氧乐酶克服药物降解挑战对非结核分枝杆菌进行奥马环素药物敏感性测试。
Tuberculosis (Edinb). 2024 Jul;147:102519. doi: 10.1016/j.tube.2024.102519. Epub 2024 May 13.
5
Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians.非结核分枝杆菌感染治疗中的药物治疗考量：临床医生入门指南
Open Forum Infect Dis. 2024 Mar 15;11(4):ofae128. doi: 10.1093/ofid/ofae128. eCollection 2024 Apr.
6
Therapy of Infections in Solid Organ Transplant Patients.实体器官移植患者感染的治疗
Microorganisms. 2024 Mar 16;12(3):596. doi: 10.3390/microorganisms12030596.
7
activity of omadacycline against clinical isolates of .奥马环素对.临床分离株的活性。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0168623. doi: 10.1128/aac.01686-23. Epub 2024 Mar 27.
8
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.奥马环素的药代动力学/药效学及在中空纤维系统模型中对多重耐药菌的疗效。
Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.
9
Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.非结核分枝杆菌病：新型候选药物和再利用药物研发的进展与突破。
Front Cell Infect Microbiol. 2023 Oct 2;13:1243457. doi: 10.3389/fcimb.2023.1243457. eCollection 2023.
10
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.奥马环素治疗非结核分枝杆菌感染的临床疗效和安全性的长期评估：一项回顾性、多中心真实世界健康结局的队列研究。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0082423. doi: 10.1128/aac.00824-23. Epub 2023 Sep 28.
本文引用的文献
1
Omadacycline for the Treatment of Disease: A Case Series.奥马环素治疗疾病：病例系列
Open Forum Infect Dis. 2020 Sep 9;7(10):ofaa415. doi: 10.1093/ofid/ofaa415. eCollection 2020 Oct.
2
Early Experience With Eravacycline for Complicated Infections.依拉环素用于复杂感染的早期经验
Open Forum Infect Dis. 2020 Mar 2;7(5):ofaa071. doi: 10.1093/ofid/ofaa071. eCollection 2020 May.
3
Omadacycline: A Modernized Tetracycline.奥马环素：一种现代化的四环素类药物。
Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S1-S5. doi: 10.1093/cid/ciz394.
4
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .新型四环素类似物奥马环素和依拉环素对.耐药临床分离株的活性
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
5
Activities of Omadacycline against Rapidly Growing Mycobacteria.奥马环素对快速生长分枝杆菌的活性。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02522-18. Print 2019 May.
6
Omadacycline for Community-Acquired Bacterial Pneumonia.奥马环素治疗社区获得性细菌性肺炎。
N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201.
7
Complex Infections: A Retrospective Cohort Study.复杂感染：一项回顾性队列研究
Open Forum Infect Dis. 2018 Feb 9;5(2):ofy022. doi: 10.1093/ofid/ofy022. eCollection 2018 Feb.
8
Treatment of Non-Tuberculous Mycobacterial Lung Disease.非结核分枝杆菌肺病的治疗
Curr Treat Options Infect Dis. 2016 Dec;8(4):275-296. doi: 10.1007/s40506-016-0086-4. Epub 2016 Oct 11.
9
Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report.非结核分枝杆菌（NTM）肺部感染以患者为中心的研究重点。一份NTM研究联盟研讨会报告。
Ann Am Thorac Soc. 2016 Sep;13(9):S379-84. doi: 10.1513/AnnalsATS.201605-387WS.
10
Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex.脓肿分枝杆菌复合群中的诱导性和获得性克拉霉素耐药性
PLoS One. 2015 Oct 8;10(10):e0140166. doi: 10.1371/journal.pone.0140166. eCollection 2015.
Zotero 插件